Other

Noncontrolling interests in subsidiaries

Gilead Sciences Noncontrolling interests in subsidiaries remained flat by 0.0% to -$84.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2016
Last reportedQ1 2026

How to read this metric

Changes reflect the acquisition or divestiture of minority stakes in subsidiaries or the relative profitability of those specific entities.

Detailed definition

This represents the portion of equity in a subsidiary that is not attributable, directly or indirectly, to the parent co...

Peer comparison

Common in companies with complex organizational structures and joint ventures.

Metric ID: other_minority_interest

Historical Data

2 periods
 Q4 '25Q1 '26
Value-$84.00M-$84.00M
QoQ Change—+0.0%
Range-$84.00M – -$84.00M

Noncontrolling interests in subsidiaries at Other Companies

Merck & Co. logo
Merck & Co.MRKView metric
AbbVie logo
AbbVieABBVView metric
Roivant Sciences logo
Roivant SciencesROIVView metric
Danaher logo
DanaherDHRView metric
Royalty Pharma logo
Royalty PharmaRPRXView metric
Pfizer logo
PfizerPFEView metric

Frequently Asked Questions

What is Gilead Sciences's noncontrolling interests in subsidiaries?
Gilead Sciences (GILD) reported noncontrolling interests in subsidiaries of -$84.00M in Q1 2026.
What does noncontrolling interests in subsidiaries mean?
The portion of a subsidiary's equity owned by outside investors.